Introduzzjoni: L-użu tat-teknoloġija tal-istampar 3D fil-manifattura tad-droga għandu potenzjal kbir għall-iżvilupp minħabba li jista 'jikkontrolla b'mod preċiż l-istruttura tal-pori tal-pillola u jippersonalizza d-drogi skont il-ħtiġijiet attwali tal-pazjenti. Qasam ta' riċerka u esperimentazzjoni.
△ 3D printed tablets can be dissolved quickly, the picture comes from Aprecia
Fit-13 ta 'Frar, 2022, l-Ors Antartiku ġie infurmat li riċerkaturi mill-Università ta' Queensland (UG) nedew dokument dwar ir-rwol tal-istampar 3D fil-provvista ta 'mediċina personalizzata għall-pazjenti fil-futur, u ppubblikaw karta relatata.
Skont Liam Krueger, spiżjar, student tal-PhD fl-Università ta’ Queensland u awtur ewlieni tal-karta, it-teknoloġija tal-istampar 3D hija biżżejjed biex tippermetti stampar preċiż ta’ dożi speċjalizzati fuq-sit fi sptarijiet u spiżeriji fil-ftit snin li ġejjin . Permezz ta 'din ir-riċerka, ir-riċerkaturi jittamaw li jaċċelleraw l-iżvilupp ta' mediċini stampati 3D fl-Awstralja u barra.
Kruger said: "3D printing technology is often used in other medical settings such as dentistry, orthopaedic implants, however in the pharmaceutical field, the utilization of 3D printing technology is lagging behind. Through this research, we hope to promote 3D printing The development of pharmaceutical technology, this is an opportunity for the future of the Australian pharmaceutical industry."
△Spritam is the world's first FDA-approved 3D-printed drug, marketed by Aprecia Pharmaceuticals. Used to treat seizures, 3D-printed pills have higher porosity than traditionally manufactured pills, which means they dissolve and act faster in the body. Image via Aprecia
Avvanzi fl-Istampar 3D fil-Farmaċewtiċi
Il-manifattura addittiva hija maħsuba ħafna li toffri ħafna vantaġġi għall-iżvilupp kliniku farmaċewtiku, bħall-personalizzazzjoni ta' trattamenti bbażati fuq il-ħtiġijiet tal-pazjent, it-tħaffif tal-ħinijiet tal-kunsinna tad-droga, u li tippermetti trattament fuq-talba, iżda t-tranżizzjoni tat-3D- it-teknoloġija tad-droga stampata mil-laboratorju sal-klinika għadha fil-bidu tagħha. stadju tal-bidu-up.
△The application of 3D printing in the pharmaceutical industry, the picture comes from FabRx
There have been some notable developments in this area, though, notably Aprecia, which won the first FDA approval for a 3D-printed drug back in 2015. Aprecia's drug Spritam has been approved to treat epilepsy, and they have since continued to scale up production through a partnership with RD company Battelle.
Aprecia żviluppat mediċini personalizzati biex jittratta mard metaboliku rari fit-tfal permezz ta 'pjattaforma flessibbli tal-manifattura tad-droga, u ħolqot pilloli stampati 3D b'mudelli tal-Braille u tal-qamar biex jgħinu pazjenti b'indeboliment tal-vista jieħdu l-mediċini tagħhom.
Barra minn hekk, il-kumpanija farmaċewtika globali Merck nediet proġett konġunt ma 'AMCM, kumpanija EOS, biex tiżviluppa u tipproduċi pilloli farmaċewtiċi stampati 3D fl-2020, l-ewwel għal provi kliniċi u wara għall-produzzjoni kummerċjali.
Fiċ-Ċina, hemm ukoll ftit kumpaniji involuti fir-riċerka tad-droga tal-istampar 3D. L-aktar wieħed rappreżentattiv huwa Nanjing Triassic, li ġie stabbilit fl-2015. Huma impenjati li jibnu pjattaforma ġdida tat-teknoloġija tad-droga tal-istampar 3D. Żvilupp diġitali, għat-teknoloġija proprjetarja tal-katina kollha ta 'produzzjoni intelliġenti. Fil-preżent, bħala l-ewwel kumpanija farmaċewtika Ċiniża magħżula għall-proġett tat-teknoloġija emerġenti tal-FDA tal-Istati Uniti, Triassic qed tipparteċipa fil-formulazzjoni tal-istandard tal-industrija farmaċewtika tal-istampar 3D tal-Farmakopea tal-Istati Uniti.
Id-dejta turi li Triassic tokkupa aktar minn 1/5 tan-numru ta 'applikazzjonijiet għal privattivi fil-qasam globali tad-droga tal-istampar 3D, u waslet biex tibni linja ta' produzzjoni ta 'droga tal-istampar 3D kontinwu u intelliġenti b'kapaċità ta' produzzjoni annwali ta '50 miljun biċċa.
Il-pilloli stampati 3D huma l-futur tal-mediċina?
L-Università ta 'Queensland wettqet l-aħħar riċerka fil-qasam tal-mediċini stampati 3D, li turi li t-teknoloġija issa hija sofistikata biżżejjed biex tiġi skjerata fi sptarijiet u spiżeriji fil-futur.
"3D printing technology can tailor a drug to a patient to ensure it has the exact dose or combination for a specific need," Krueger said. "Through 3D printing, we can combine five pills into one and even change the size of the pills. , shape, color, taste or texture."
Minkejja l-vantaġġi ċari tal-mediċini stampati 3D, għad hemm xi sfidi li jridu jiġu indirizzati għal adozzjoni mifruxa f'ambjenti mediċi.
Waħda mill-isfidi hija l-ħin tal-istampar. Konvenzjonalment, tieħu madwar 3 minuti biex tipprintja pillola ta 'daqs standard 10x3mm, u madwar 45 minuta għal lott ta' 28 pillola. Dan huwa twil wisq għal mediċina li trid tiġi skjerata fuq-talba fi klinika, u jeħtieġ li titqassar biex tkun prattika fid-dinja reali.
Madankollu, ko-awtur tad-dokument, il-Professur Assoċjat Amirali Popat fl-Università ta’ Queensland jemmen li l-istampar 3D jista’ jnaqqas in-numru ta’ mediċini li pazjent ikollu jieħu.
"Polypharmacy is the use of five or more drugs at the same time, and about two-thirds of 75-year-old Australians are in such treatment," he said. "The real benefit of 3D-printed pills lies with the consumer or the patient, although There's still some way to go before it happens, but it's a very exciting development."
The research is the beginning of the University of Queensland's research on the feasibility of using 3D printing technology for personalised medicine in the real world, and the data collected so far is promising, the researchers said.
Co-author Chris Freeman (National President of the Pharmaceutical Association of Australia) said: "In the future, 3D printing could help people who need to take multiple medicines to take the right medicine at the right time and in the right dose."
More information about this study can be found in the paper titled "3D printing: Potential clinical applications for personalised solid dosemedications", published in the Medical Journal of Australia. Co-authors of the study are L. Krueger, J. Miles, K. Steadman, T. Kumeria, C. Freeman and A. Popat.
